SciDev (ASX:SDV) Jumps as Newmont Contract Supports Its Recovery Push

Aditi Sarkar

05 August 2026 02:05 PM AEST

SciDev (ASX:SDV) Jumps as Newmont Contract Supports Its Recovery Push

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

SciDev shares are trading 22.22% higher at AUD 0.165 during the 5 August 2026 session.
SciDev secured a new AUD 6mn chemistry contract with Newmont in June 2026.
Volume currently stands at 1,222,257 shares and market capitalisation is approximately AUD 31.36mn.
Delivery of the Newmont contract, FY26 revenue, margins, cash conversion and the recovery of water and energy activity are the main measures.

SciDev (ASX:SDV) is drawing attention during the 5 August 2026 session as the share price trades 22.22% higher at AUD 0.165. The stock is trading within a range of AUD 0.140 to AUD 0.170, while 1,222,257 shares have changed hands. The move is placing renewed focus on the company’s latest operational, exploration or corporate development.

The one-year share-price change currently stands at -47.62%. That longer record provides context for the intraday rise, particularly where a low share price or limited liquidity can magnify percentage movements. Continued buying interest will depend on future announcements and execution.

Company Overview

SciDev supplies specialised chemistry and water-treatment solutions to mining, infrastructure and industrial customers in Australia and overseas.

Latest Company Development

SciDev secured a new AUD 6mn chemistry contract with Newmont in June 2026. Earlier trading information showed third-quarter EBITDA of approximately AUD 1.1mn and year-to-date EBITDA of AUD 2.2mn, with the quarterly margin improving to 6%.

Share Price and Market Snapshot

As at 5 August 2026, SDV is trading at AUD 0.165, up 22.22% during the session. The shares have traded between AUD 0.140 and AUD 0.170, while volume currently stands at 1,222,257. At the current price, the company has a market capitalisation of approximately AUD 31.36mn. The one-year share-price change is -47.62%.

What Investors May Watch Next

Delivery of the Newmont contract, FY26 revenue, margins, cash conversion and the recovery of water and energy activity are the main measures.

The next formal announcement may show whether the current price movement is being supported by measurable progress. Delivery against stated milestones, available funding and the quality of technical or commercial results will remain important.

Risks

The intraday share-price gain may reverse if expectations run ahead of company progress.
Exploration, development, contract or transaction milestones may be delayed or unsuccessful.
Commodity prices, customer demand or project economics may weaken.
Additional capital could dilute existing shareholders or increase financial pressure.
Low liquidity and broader market sentiment may amplify price volatility.

FAQs

Q: Why are SciDev shares attracting attention?

A:The shares are trading 22.22% higher at AUD 0.165 during the 5 August 2026 session.

Q: What is the latest development at SciDev?

A:SciDev secured a new AUD 6mn chemistry contract with Newmont in June 2026. Earlier trading information showed third-quarter EBITDA of approximately AUD 1.1mn and year-to-date EBITDA of AUD 2.2mn, with the quarterly margin improving to 6%.

Q: What is SciDev’s current market capitalisation?

A:At the current share price, the market capitalisation is approximately AUD 31.36mn.

Q: What should investors watch next?

A:Delivery of the Newmont contract, FY26 revenue, margins, cash conversion and the recovery of water and energy activity are the main measures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.